journal article·2022-09-28

Aptamer-Gold Nanocage Composite for Photoactivated Immunotherapy

Wen Song, Jing-Jing Hu, Shu-Jun Song, Yi Xu, Hang Yang, Fan Yang, Ying Zhou, Tao Yu, Wen-Xiu Qiu

ACS Applied Materials & Interfaces· Volume 14· Issue 38
Publisher page

Abstract

Immune checkpoint blockade (ICB) has been hailed as the hope for conquering cancer as ICB could produce a significant and durable response to tumor cells. However, the high cost and severe side effects of ICB drugs limited their application for further anticancer therapy. Here, we developed a photoactivated immunotherapy nanoplatform (Apt@AuNC). This nanoplatform could target tumor tissues via enhanced penetration retention (EPR) effect and the aptamer (Apt) could be released from Apt@AuNC in tumor sites via illumination. The immune system in the tumor area was then activated after the combination of Apt and PD-1 protein. The heat generated from AuNC was able to continue killing tumor cells. This nanoplatform could not only achieve the precise immunotherapy but also significantly facilitate the anticancer efficacy.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: Nanoplatforms for cancer theranostics · Immunotherapy and Immune Responses · Advanced biosensing and bioanalysis techniques

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Institute of Biology and Medicine, College of Life Science and Health, Wuhan University of Science and Technology, Wuhan, Hubei 430081, P.R. China

State Key Laboratory of Biogeology and Environmental Geology, Faculty of Materials Science and Chemistry, China University of Geosciences, Wuhan 430074, P.R. China

Department of Orthopaedics, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200025, P.R. China

Funding

National Natural Science Foundation of China

References (26)

Show source-provided references
1. 10.1038/s41577-019-0218-410.1038/s41577-019-0218-4 ↗
2. 10.1002/adhm.20180042410.1002/adhm.201800424 ↗
3. 10.1200/JCO.2018.36.15_suppl.307410.1200/JCO.2018.36.15_suppl.3074 ↗
4. 10.1073/pnas.191789111710.1073/pnas.1917891117 ↗
5. 10.1021/acs.accounts.0c0072410.1021/acs.accounts.0c00724 ↗
6. 10.1021/acs.accounts.0c0033910.1021/acs.accounts.0c00339 ↗
7. 10.1021/jacs.1c0201610.1021/jacs.1c02016 ↗
8. 10.1039/D0CC06032A10.1039/D0CC06032A ↗
9. 10.1038/mtna.2015.1110.1038/mtna.2015.11 ↗
10. 10.1021/jacs.2c0401710.1021/jacs.2c04017 ↗
11. 10.1021/acsami.1c1502510.1021/acsami.1c15025 ↗
12. 10.1021/acsnano.7b0911210.1021/acsnano.7b09112 ↗
13. 10.1021/ja504299510.1021/ja5042995 ↗
14. 10.1002/anie.20150918210.1002/anie.201509182 ↗
15. 10.1002/anie.20170333210.1002/anie.201703332 ↗
16. 10.1038/nprot.2007.32610.1038/nprot.2007.326 ↗
17. 10.1021/acs.nanolett.8b0267010.1021/acs.nanolett.8b02670 ↗
18. 10.1021/acsami.0c0559610.1021/acsami.0c05596 ↗
19. 10.1021/acsnano.9b0649210.1021/acsnano.9b06492 ↗
20. 10.1016/j.immuni.2005.10.00510.1016/j.immuni.2005.10.005 ↗
21. 10.1073/pnas.091060910710.1073/pnas.0910609107 ↗
22. 10.1073/pnas.180554211510.1073/pnas.1805542115 ↗
23. 10.1038/onc.2014.28610.1038/onc.2014.286 ↗
24. 10.1002/ptr.535410.1002/ptr.5354 ↗
25. 10.1053/j.seminoncol.2015.05.01510.1053/j.seminoncol.2015.05.015 ↗
26. 10.1136/gutjnl-2016-31158510.1136/gutjnl-2016-311585 ↗